OpportunityTitle: Studies Addressing Rare Neurodegenerative Diseases including ALS
Description: The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
GrantorContactEmailDescription: terrin.brown@fda.hhs.gov